Search

Your search keyword '"Seki, Atsuyoshi"' showing total 10 results
Start Over Author "Seki, Atsuyoshi" Publication Year Range Last 3 years
10 results on '"Seki, Atsuyoshi"'

1. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Author

Yumita, Sae, Ogasawara, Sadahisa, Nakagawa, Miyuki, Maruta, Susumu, Okubo, Tomomi, Itokawa, Norio, Iino, Yotaro, Obu, Masamichi, Haga, Yuki, Seki, Atsuyoshi, Kogure, Tadayoshi, Ishino, Takamasa, Ogawa, Keita, Fujiwara, Kisako, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, Kojima, Ryuta, Kanzaki, Hiroaki, Koroki, Keisuke, Inoue, Masanori, Kobayashi, Kazufumi, Kiyono, Soichiro, Nakamura, Masato, Kanogawa, Naoya, Saito, Tomoko, Kondo, Takayuki, Nakagawa, Ryo, Nakamoto, Shingo, Muroyama, Ryosuke, Chiba, Tetsuhiro, Itobayashi, Ei, Atsukawa, Masanori, Koma, Yoshihiro, Azemoto, Ryosaku, Ito, Kenji, Mizumoto, Hideaki, Kato, Jun, and Kato, Naoya

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 3 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma

Author

Chiba, Tetsuhiro, primary, Miyagi, Satoru, primary, Saraya, Atsunori, primary, Aoki, Ryutaro, primary, Seki, Atsuyoshi, primary, Morita, Yohei, primary, Yonemitsu, Yutaka, primary, Yokosuka, Osamu, primary, Taniguchi, Hideki, primary, Nakauchi, Hiromitsu, primary, and Iwama, Atsushi, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 2 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma

Author

Chiba, Tetsuhiro, primary, Miyagi, Satoru, primary, Saraya, Atsunori, primary, Aoki, Ryutaro, primary, Seki, Atsuyoshi, primary, Morita, Yohei, primary, Yonemitsu, Yutaka, primary, Yokosuka, Osamu, primary, Taniguchi, Hideki, primary, Nakauchi, Hiromitsu, primary, and Iwama, Atsushi, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure Legends 1-3 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma

Author

Chiba, Tetsuhiro, primary, Miyagi, Satoru, primary, Saraya, Atsunori, primary, Aoki, Ryutaro, primary, Seki, Atsuyoshi, primary, Morita, Yohei, primary, Yonemitsu, Yutaka, primary, Yokosuka, Osamu, primary, Taniguchi, Hideki, primary, Nakauchi, Hiromitsu, primary, and Iwama, Atsushi, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 1 from The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma

Author

Chiba, Tetsuhiro, primary, Miyagi, Satoru, primary, Saraya, Atsunori, primary, Aoki, Ryutaro, primary, Seki, Atsuyoshi, primary, Morita, Yohei, primary, Yonemitsu, Yutaka, primary, Yokosuka, Osamu, primary, Taniguchi, Hideki, primary, Nakauchi, Hiromitsu, primary, and Iwama, Atsushi, primary

Published
2023
Full Text
View/download PDF

7. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice

Author

Nakagawa, Miyuki, primary, Inoue, Masanori, additional, Ogasawara, Sadahisa, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Iino, Yotaro, additional, Obu, Masamichi, additional, Haga, Yuki, additional, Seki, Atsuyoshi, additional, Kikuchi, Yasuharu, additional, Kogure, Tadayoshi, additional, Yumita, Sae, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Taida, Takashi, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Shinozaki, Masami, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

8. Analysis of hyperprogressive disease due to atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma

Author

Yumita, Sae, primary, Ogasawara, Sadahisa, additional, Nakagawa, Miyuki, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Iino, Yotaro, additional, Obu, Masamichi, additional, Haga, Yuki, additional, Seki, Atsuyoshi, additional, Kogure, Tadayoshi, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

9. Analysis of hyperprogressive disease due to atezolizumab combined with bevacizumab treatment in patients with advanced hepatocellular carcinoma

Author

Yumita, Sae, primary, Ogasawara, Sadahisa, additional, Nakagawa, Miyuki, additional, Maruta, Susumu, additional, Okubo, Tomomi, additional, Itokawa, Norio, additional, Iino, Yotaro, additional, Oobu, Masamichi, additional, Haga, Yuki, additional, Seki, Atsuyoshi, additional, Kogure, Tadayoshi, additional, Ishino, Takamasa, additional, Ogawa, Keita, additional, Fujiwara, Kisako, additional, Iwanaga, Terunao, additional, Fujita, Naoto, additional, Sakuma, Takafumi, additional, Kojima, Ryuta, additional, Kanzaki, Hiroaki, additional, Koroki, Keisuke, additional, Inoue, Masanori, additional, Kobayashi, Kazufumi, additional, Kiyono, Soichiro, additional, Nakamura, Masato, additional, Kanogawa, Naoya, additional, Saito, Tomoko, additional, Kondo, Takayuki, additional, Nakagawa, Ryo, additional, Nakamoto, Shingo, additional, Muroyama, Ryosuke, additional, Chiba, Tetsuhiro, additional, Itobayashi, Ei, additional, Atsukawa, Masanori, additional, Koma, Yoshihiro, additional, Azemoto, Ryosaku, additional, Ito, Kenji, additional, Mizumoto, Hideaki, additional, Kato, Jun, additional, and Kato, Naoya, additional

Published
2022
Full Text
View/download PDF

10. Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice.

Author

Nakagawa, Miyuki, Inoue, Masanori, Ogasawara, Sadahisa, Maruta, Susumu, Okubo, Tomomi, Itokawa, Norio, Iino, Yotaro, Obu, Masamichi, Haga, Yuki, Seki, Atsuyoshi, Kikuchi, Yasuharu, Kogure, Tadayoshi, Yumita, Sae, Ishino, Takamasa, Ogawa, Keita, Fujiwara, Kisako, Iwanaga, Terunao, Fujita, Naoto, Sakuma, Takafumi, and Kojima, Ryuta

Subjects
BEVACIZUMAB, HEPATOCELLULAR carcinoma, ATEZOLIZUMAB, VASCULAR endothelial growth factors, FATTY liver, CLINICAL trials
Abstract

Background: Although the efficacy of atezolizumab has been demonstrated in randomized controlled trials, its long‐term efficacy and association with adverse events in real‐world practice are unknown. This study was designed to shed light on these issues. Methods: In this multicenter retrospective study, data were collected from patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab in seven institutions in Japan. The authors focused on the efficacy and adverse events related to vascular endothelial growth factor (VEGF) inhibition. Results: A total of 123 patients were enrolled in this study. The median progression‐free survival (PFS) for the first‐line treatment group was 8.0 months (95% confidence interval [CI], 6.1–9.9), whereas the median PFS for the second‐ or later‐line treatment group was 4.1 months (95% CI, 2.6–5.7), which was significantly worse than that of the first‐line treatment group (p =.005). Twenty‐seven patients had interrupted bevacizumab treatment. Proteinuria accounted for the largest proportion of bevacizumab treatment interruptions. The cumulative incidence rate of bevacizumab interruption due to anti‐VEGF–related adverse events was significantly higher in patients with hypertension and/or diabetes mellitus than in those without (p =.026). The landmark analysis showed that patients experienced bevacizumab interruption by 24 weeks from treatment initiation had poorer PFS than those who did not (p =.013). Conclusions: The PFS of atezolizumab plus bevacizumab as first‐line treatment mostly replicates that of a global phase 3 trial. Interrupted bevacizumab treatment was more common in patients with hypertension and/or diabetes mellitus, which may be associated with worsening long‐term PFS. Plain language summary: Atezolizumab plus bevacizumab has been the standard front line systemic therapy for advanced hepatocellular carcinoma.With the growing incidence of fatty liver due to metabolic syndrome as a background liver disease for hepatocellular carcinoma, the rate of comorbid hypertension and diabetes mellitus has been increasing accordingly.The present study demonstrated the cumulative incidence rate of bevacizumab interruption due to anti‐VEGF–related adverse events was significantly higher in patients with hypertension and/or diabetes mellitus.The landmark analysis clarified that interruption of bevacizumab might be a risk of impaired efficacy of atezolizumab plus bevacizumab over the long term in patients with advanced hepatocellular carcinoma. This report demonstrated that the cumulative incidence rate of bevacizumab interruption due to anti‐VEGF–related adverse events was significantly higher in patients with comorbid hypertension and/or diabetes mellitus during atezolizumab plus bevacizumab for advanced hepatocellular carcinoma. Interruption of bevacizumab might be a risk of impaired efficacy of atezolizumab plus bevacizumab over the long term in patients with advanced hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results